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Dear Editor,
Multiple myeloma (MM) is a clonal plasma cell disorder
whose prognosis is driven by the presence or absence of a
wide gamut of primary (trisomies and translocations) and
secondary (monosomies/deletions and amplifications)
genetic abnormalities. Translocations involving the
immunoglobulin heavy chain (IgH) region on chromo-
some 14 and one of its partners on chromosomes 4, 6, 11,
16 and 20 occur in approximately 40% of MM patients.
Among the IgH translocations, t(11;14) is the most
commonly observed lesion (occurring in 16–24% of MM
patients), while t(14;16) is rather uncommon (<5% of
patients, in most reported series)1–3. The International
Myeloma Working Group (IMWG)4,5 and the m-
SMART6 risk-stratification currently consider t(11;14) as
a standard-risk chromosomal abnormality7, hile t(4;14),
t(14;16) and t(14;20) have been associated with poor
survival, although the data on the prognostic impact of
t(14;16) in the era of newer anti-myeloma drugs have not
been extensively reported and few retrospective studies
have reported conflicting results on the prognostic sig-
nificance of this abnormality1,8,9. t(14;16)(q32;q23)
involves the IgH locus and the c-musculoaponeurotic
fibrosarcoma (c-MAF) oncogene locus, the latter likely
being responsible, at least partially, of the MAF-mediated
innate resistance to proteasome inhibition, a backbone
treatment in current myeloma regimens10.
Having considered the availability of newer combination
regimens and the recent outcomes in the treatment of
MM, we conducted a multi-institutional collaborative
study among patients harboring t(14;16) diagnosed at
different European and American centers, with the aim of
describing their clinical features and investigating the
prognostic value of t(14;16).
Newly diagnosed (ND)MM patients meeting the IMWG
criteria for symptomatic MM were included in the ana-
lysis. Patients were diagnosed between December 2006
and March 201711,12 and registered in databases of: clin-
ical trials coordinated by the Italian group and with cen-
tralized fluorescent in situ hybridization (FISH) at the
Torino site (TO, Italy; see Table S1 for the list of source
trials with centralized FISH at TO); the Winship Cancer
Institute (WCI, Emory University, Atlanta US); and the
Department of Clinical Therapeutics, National and
Kapodistrian University of Athens (NKUA, Greece). Data
regarding demographic and baseline characteristics,
treatments administered, responses to treatment and
survival outcomes were collected from the institutional
review board databases approved by the respective cen-
ters. Response to treatment and disease progression were
assessed using the IMWG uniform response criteria13,14.
FISH analysis was performed on CD138+ enriched
bone marrow plasma cells; the cut-off levels ranged from
10 to 20% for numerical aberrations and from 5 to 15% for
IgH translocations.
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Progression-free survival (PFS) was calculated from the
date of initial therapy to either the date of the first relapse
or death due to any cause; overall survival (OS) was cal-
culated from the date of initial therapy to the date of
death. PFS and OS were estimated using the
Kaplan–Meier method and compared between groups
using the log-rank test. We used the Cox proportional
hazards model to identify factors affecting PFS and OS. A
two-tailed P-value < 0.05 was considered significant for all
statistical tests. Data were analyzed as of April 2018 using
R (v3.1.1).
We identified 123 NDMM patients with t(14;16)-posi-
tive FISH at diagnosis (TO, n= 76/1678; WCI, n= 29/
926; NKUA, n= 18/571) with a median age at diagnosis of
66 years (range, 38–87 years; see Table S2. Patient char-
acteristics at diagnosis). Twenty-three percent of patients
had lactate dehydrogenase (LDH) levels above the upper
limit of normal; creatinine ≥2mg/dl and hypercalcemia
were observed in 16% of patients. Most of the patients
presented with International Staging System (ISS) stages 2
(34%) or 3 (43%) and with concomitant chromosomal
abnormalities, including del(13q) (71%), gain(1q) (51%),
and del(17p) (23%).
All but one patient received novel agents as part of
induction therapy, including immunomodulatory drugs
(42%), proteasome inhibitors (29%) or a combination of
both (28%) (Table S2). Autologous stem-cell transplan-
tation (ASCT) was performed in 42% of patients, 28%
upfront and 14% at relapse; 41% of patients received
maintenance therapy.
The objective response rate to first-line treatment was
85% (partial response [PR]: 26%; very-good PR [VGPR]:
29%; at least complete response [≥CR]: 28%); 5% of
patients were primary refractory to induction therapy.
After a median follow-up of 53 months (95% CI 35–63),
median PFS and OS for the entire cohort were,
respectively, 19 months (95% CI 16–30) and 53 months
(95% CI 36–63), with 39% of patients being alive at
5 years.
t(14;16)-positive patients with del(17p), del(13q), or
amp(1q) (n= 101) had significantly shorter median PFS
(17 months vs. NR; HR: 3.33, p= 0.04) and inferior,
although not statistically significant, OS (median,
46 months vs. NR; HR: 1.54, p= 0.47), as compared to
those without additional chromosomal abnormalities (n
= 10) (Fig. 1). More specifically, the risk of progression or
death of t(14;16) patients increased by 1.35 fold in patients
also harboring del(17p) (p= 0.23), by 1.64 in presence of
del(13q) (p= 0.05) and by 2.2 in patients carrying amp
(1q) (p= 0.02); a shorter OS, although not statistically
significant, was observed in presence of del(17p) (HR: 1.3;
p= 0.47) and amp(1q) (HR: 1.7; p= 0.16), whereas a
significantly shorter OS was observed with del(13q) (HR:
1.96; p= 0.04).
Among younger, ASCT-eligible patients, median PFS
and OS were, respectively, 24 (95% CI 17–38) and
52 months (95% CI 34–69); ASCT upfront prolonged
median PFS (36 vs. 17 months; HR: 0.5, p= 0.036), as
compared to standard-dose chemotherapy without ASCT.
Maintenance therapy significantly prolonged median PFS,
as compared to no maintenance (36 vs. 19 months, HR:
0.59; p= 0.045). The achievement of ≥CR as best response
to treatment was related to prolonged PFS (HR 0.29, p <
0.001), as compared to the achievement of PR/VGPR.
In a multivariate analysis, ISS-3 (HR: 1.79; p= 0.014)
and the presence of an additional chromosomal
abnormality (del(17p), del(13q) or amp(1q); HR: 3.24; p=
0.049) were associated to a shorter PFS, while ISS-3 (HR:
1.6; p= 0.09), hypercalcemia (HR: 2.4; p= 0.043) and
elevated LDH (HR: 2.13; p= 0.026) were associated with a
significantly shorter OS (see Table S3. Univariate and
multivariate analyses).
PFS, progression-free survival OS, overall survival CAs, chromosomal abnormalities HR, hazard ratio p, p-value
Fig. 1 Time-to-event analysis. Kaplan–Meier progression-free survival (a PFS progression-free survival) and overall survival (b OS overall survival)
curves in t(14;16)-positive patients. Blue curve: t(14;16)-positive patients overall; orange curve: t(14;16)-positive patients with additional CAs
chromosomal abnormalities [del(17p) and/or del(13q) and/or amp(1q)]; green curve: t(14;16)-positive patients without additional CAs.
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To our knowledge, this is one of the largest studies on
NDMM patients harboring t(14;16) describing their
clinical features and survival outcomes in the era of novel
agents.
In a previous report from the Mayo Clinic (2003), the
presence of t(14;16) was associated with shorter PFS
(median, 9 vs. 30 months) and OS (median, 16 vs.
41 months), as compared to t(14;16)-negative MM (see
Table S4. Previous reports of t(14;16))1. However, that
analysis included a limited number of patients (n= 15)
before the introduction of novel agents. These results
were not confirmed in a larger cohort of patients (n=
1003) treated by the Intergroupe Francophone du Myé-
lome (IFM): here, t(14;16) was detected in 32 patients and
was not prognostically significant9. Nonetheless, the
IMWG listed t(14;16) among the unfavorable high-risk
chromosomal abnormalities7. Narita et al. showed that
both PFS (median, 0.6 vs. 1.2 years) and OS (median, 3.06
vs. 4.40 years) were significantly shorter among t(14;16)-
positive patients (N= 35) than among t(14;16)-negative
patients (N= 124)8.
According to our analysis, the majority of t(14;16)
patients presented at diagnosis with at least one other
high-risk feature, such as additional chromosomal
abnormality (81%), ISS-3 (43%) and elevated LDH (23%),
which were all significantly associated with inferior sur-
vival (Table S3).
Median PFS and OS for the entire cohort were 19 and
53 months. Although this study does not include a control
population, the median OS of t(14;16) patients was
shorter than that observed in a cohort of patients treated
with novel agents (median, 72 months)15. Interestingly,
t(14;16)-positive patients who harbored additional chro-
mosomal abnormalities [del(17p), del(13q), or amp(1q)]
displayed worse PFS (HR: 3.33) and OS (HR: 1.54), as
compared to t(14;16) patients without further chromo-
somal abnormalities (Table S3). Despite the limited
number of patients, this observation casts doubt on the
unfavorable prognostic significance of isolated t(14;16),
which seems to occur infrequently, and raises the ques-
tion of whether the poor prognosis of these patients is
related to t(14;16) per se rather than to the presence of
additional genetic lesions.
Our analysis also confirmed the role of upfront ASCT in
prolonging PFS and OS and the role of maintenance
treatment in deepening the quality of response and
prolonging PFS as compared to fixed-duration therapy.
This study has some limitations. First, the absence of a
control population limits our ability to precisely estimate
the risk conferred by the presence of t(14;16) in the era of
novel agents. Secondly, the heterogeneity of treatment
therapies does not allow us to speculate on the efficacy of
specific regimens. Finally, since 62% of patients in this
cohort were enrolled in clinical trials, the rates of patients
with renal failure or aggressive disease requiring
immediate treatment were underestimated and conse-
quently affected the results. Despite these caveats, PFS
and OS of t(14;16) patients in the era of novel agents seem
to be shorter than those of standard-risk patients15.
Whether the poor prognosis of t(14;16) patients is asso-
ciated with t(14;16) per se or with the frequent co-
existence of other high-risk features is an issue that needs
to be addressed.
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